Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, which are rare, chronic kidney diseases with no approved treatments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Buy Rating Affirmed Amid FDA Approval and Strategic Market Positioning
- Hold Rating for Apellis Pharmaceuticals Amid Competitive Challenges and Reimbursement Concerns
- Australia’s TGA approves Apellis’ SYFOVRE for GA related to AMD
- Apellis’ Syfovre can capitalize on competitor headwinds, says JPMorgan
- Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes